Literature DB >> 1849971

Presence and distribution of human papillomavirus sense and antisense RNA transcripts in genital cancers.

G D Higgins1, D M Uzelin, G E Phillips, C J Burrell.   

Abstract

RNA transcription in eight human papillomavirus (HPV) type 16-positive genital carcinomas and in two cervical squamous cell carcinoma (SCC)-derived cell lines was analysed by in situ hybridization using 125I-labelled subgenomic riboprobes. Transcripts corresponding to the E6 and E7 open reading frames were always present, except within the keratinizing layers of differentiated SCCs. Intranuclear E1 gene transcripts were detectable in both cell lines and some tumours whereas E2/E4 transcripts were absent from five of seven assessable tumours, suggesting transcription from integrated viral DNA. When mRNA sense riboprobes were used as controls, no signal was seen in the two cell lines; however, three tumours contained a focal, intense nuclear RNase-sensitive signal using mRNA sense riboprobes. This antisense RNA signal mapped across the whole genome including the noncoding region. In one tumour, the presence of antisense RNA was independently confirmed by using E7 and E2/E4 RNA probes of both orientations in RNase protection assays. Transcription of antisense RNA may be a natural feature of some HPV-positive genital tumours and its possible role in modulating cell behaviour in vivo requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849971     DOI: 10.1099/0022-1317-72-4-885

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Natural antisense transcripts of UL123 packaged in human cytomegalovirus virions.

Authors:  Cui-Qing Yang; Ling-Feng Miao; Xing Pan; Cong-Cong Wu; Simon Rayner; Edward S Mocarski; Han-Qing Ye; Min-Hua Luo
Journal:  Arch Virol       Date:  2013-07-25       Impact factor: 2.574

2.  Biological relevance of human papillomaviruses in vulvar cancer.

Authors:  Gordana Halec; Laia Alemany; Beatriz Quiros; Omar Clavero; Daniela Höfler; Maria Alejo; Wim Quint; Michael Pawlita; Francesc X Bosch; Silvia de Sanjose
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

3.  The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth.

Authors:  William C Spanos; Andrew Hoover; George F Harris; Shu Wu; Guinevere L Strand; Mary E Anderson; Aloysius J Klingelhutz; Wiljan Hendriks; Aaron D Bossler; John H Lee
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

4.  Characterization of human papillomavirus type 16 activity in separate biopsies from a carcinoma of the cervix uteri.

Authors:  D Kube; J Janda; K D Johannsmeyer; S Bergmann; U Kiessling
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

5.  YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity.

Authors:  M J O'Connor; S H Tan; C H Tan; H U Bernard
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma.

Authors:  A N Rosenthal; D Hopster; A Ryan; I J Jacobs
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

7.  Detection of human antibody against the human papillomavirus type 16 E7 protein.

Authors:  M Hashido; T Kanda; S Zanma; S Watanabe; N Komiyama; H Yoshikawa; N Yamaguchi; T Kawana; K Yoshiike
Journal:  Jpn J Cancer Res       Date:  1991-12

8.  Detection of human papillomavirus-16 in ovarian malignancy.

Authors:  Q-J Wu; M Guo; Z-M Lu; T Li; H-Z Qiao; Y Ke
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

9.  HPV E6/E7 RNA in situ hybridization signal patterns as biomarkers of three-tier cervical intraepithelial neoplasia grade.

Authors:  Mark F Evans; Zhihua Peng; Kelli M Clark; Christine S-C Adamson; Xiao-Jun Ma; Xingyong Wu; Hongwei Wang; Yuling Luo; Kumarasen Cooper
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.